Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-Current Debt: 2015-2024

Historic Non-Current Debt for Seres Therapeutics (MCRB) over the last 4 years, with Jun 2024 value amounting to $102.5 million.

  • Seres Therapeutics' Non-Current Debt rose 1.74% to $102.5 million in Q2 2024 from the same period last year, while for Jun 2024 it was $102.5 million, marking a year-over-year increase of 1.74%. This contributed to the annual value of $101.5 million for FY2023, which is 100.72% up from last year.
  • Latest data reveals that Seres Therapeutics reported Non-Current Debt of $102.5 million as of Q2 2024, which was up 0.48% from $102.0 million recorded in Q1 2024.
  • In the past 5 years, Seres Therapeutics' Non-Current Debt registered a high of $102.5 million during Q2 2024, and its lowest value of $16.1 million during Q3 2021.
  • For the 3-year period, Seres Therapeutics' Non-Current Debt averaged around $76.2 million, with its median value being $76.0 million (2023).
  • As far as peak fluctuations go, Seres Therapeutics' Non-Current Debt crashed by 35.47% in 2021, and later spiked by 215.55% in 2022.
  • Seres Therapeutics' Non-Current Debt (Quarterly) stood at $24.6 million in 2020, then grew by 0.02% to $24.6 million in 2021, then spiked by 105.30% to $50.6 million in 2022, then soared by 100.72% to $101.5 million in 2023, then climbed by 1.74% to $102.5 million in 2024.
  • Its Non-Current Debt was $102.5 million in Q2 2024, compared to $102.0 million in Q1 2024 and $101.5 million in Q4 2023.